alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 99.1

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER  PURSUANT TO 18 U.S.C. SECTION 1350,  AS ADOPTED PURSUANT TO  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I,
Arthur Zafiropoulo, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:



| |  | By:                                                     | /s/ARTHUR ZAFIROPOULO
| |  | ------------------------------------------------------- | ---------------------
| |  | Name: Arthur Zafiropoulo
Title: Chief Executive Officer

I,
Bruce Wright, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:



| |  | By:                                               | /s/BRUCE WRIGHT
| |  | ------------------------------------------------- | ---------------
| |  | Name: Bruce Wright
Title: Chief Financial Officer

---

QuickLinks
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THE FINANCIAL DATA SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED
FROM THE HANOVER COMPRESSOR COMPANY FINANCIAL STATEMENTS AS OF AND FOR THE THREE
MONTHS ENDED SEPTEMBER 30, 1999 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-END>                               SEP-30-1999
<CASH>                                           9,090
<SECURITIES>                                         0
<RECEIVABLES>                                   89,421
<ALLOWANCES>                                     1,933
<INVENTORY>                                     66,078
<CURRENT-ASSETS>                               190,388
<PP&E>                                         499,391
<DEPRECIATION>                                  72,864
<TOTAL-ASSETS>                                 683,980
<CURRENT-LIABILITIES>                           60,522
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       271,633
<OTHER-SE>                                      77,181
<TOTAL-LIABILITY-AND-EQUITY>                   683,980
<SALES>                                         24,226
<TOTAL-REVENUES>                                84,462
<CGS>                                           19,512
<TOTAL-COSTS>                                   66,169
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               1,804
<INCOME-PRETAX>                                 16,489
<INCOME-TAX>                                     6,101
<INCOME-CONTINUING>                             10,388
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    10,388
<EPS-BASIC>                                       0.36
<EPS-DILUTED>                                     0.34


</TABLE>
# Uradni list C 509I/2021

| | ISSN 1977-1045 |
| --- | --- |
| Uradni list
  Evropske unije | C 509I |
| | |
| Slovenska izdaja | Informacije in objave | Letnik 6417. december 2021 |

ISSN 1977-1045

Uradni list

Evropske unije

C 509I

Slovenska izdaja

Informacije in objave

Letnik 6417. december 2021

---

| Vsebina | Stran |
| --- | --- |
| | IV   Informacije |
| | INFORMACIJE INSTITUCIJ, ORGANOV, URADOV IN AGENCIJ EVROPSKE UNIJE |
| | Evropska komisija |
| 2021/C 509 I/01 | Povzetek sklepov Evropske unije o dovoljenjih za promet z zdravili dne 17. decembra 2021
  (Objavljeno v skladu s členom 13 ali členom 38 Uredbe (ES) št. 726/2004 Evropskega parlamenta in Sveta) | 1 |

Vsebina

Stran

IV   Informacije

INFORMACIJE INSTITUCIJ, ORGANOV, URADOV IN AGENCIJ EVROPSKE UNIJE

Evropska komisija

2021/C 509 I/01

Povzetek sklepov Evropske unije o dovoljenjih za promet z zdravili dne 17. decembra 2021
  (Objavljeno v skladu s členom 13 ali členom 38 Uredbe (ES) št. 726/2004 Evropskega parlamenta in Sveta)

(Objavljeno v skladu s členom 13 ali členom 38 Uredbe (ES) št. 726/2004 Evropskega parlamenta in Sveta

1

---

| SL | |
| --- | --- |

SL

---

IV Informacije

INFORMACIJE INSTITUCIJ, ORGANOV, URADOV IN AGENCIJ EVROPSKE UNIJE

Evropska komisija

| 17.12.2021 | SL | Uradni list Evropske unije | CI 509/1 |
| --- | --- | --- | --- |

17.12.2021

SL

Uradni list Evropske unije

CI 509/1

---

Povzetek sklepov Evropske unije o dovoljenjih za promet z zdravili dne 17. decembra 2021

(Objavljeno v skladu s členom 13 ali členom 38 Uredbe (ES) št. 726/2004 Evropskega parlamenta in Sveta (1))

(2021/C 509 I/01)

| — | Izdaja dovoljenja za promet (člen 13 Uredbe (ES) št. 726/2004 Evropskega parlamenta in Sveta): Odobrena













  Datum sprejetja sklepa | Ime zdravila | INN (mednarodno nelastniško ime) | Imetnik dovoljenja za promet | Registracijska številka v registru Skupnosti | Farmacevtska oblika | ATC (anatomsko terapevtska kemijska oznaka) | Datum obvestila |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 17.12.2021 | Xevudy | sotrovimab | GlaxoSmithKline Trading Services Limited
  Riverwalk 12, Citywest Business Campus, Dublin 24, Ireland | EU/1/21/1562 | Koncentrat za raztopino za infundiranje | Pending | 17.12.2021 |

—

Izdaja dovoljenja za promet (člen 13 Uredbe (ES) št. 726/2004 Evropskega parlamenta in Sveta): Odobrena

Datum sprejetja sklepa

Ime zdravila

INN (mednarodno nelastniško ime)

Imetnik dovoljenja za promet

Registracijska številka v registru Skupnosti

Farmacevtska oblika

ATC (anatomsko terapevtska kemijska oznaka)

Datum obvestila

17.12.2021

Xevudy

sotrovimab

GlaxoSmithKline Trading Services Limited

Riverwalk 12, Citywest Business Campus, Dublin 24, Ireland

EU/1/21/1562

Koncentrat za raztopino za infundiranje

Pending

17.12.2021

Kdor želi dobiti vpogled v javno poročilo o oceni zadevnih zdravil ter o zadevnih sklepih o zdravilih, se lahko obrne na naslov:

| European Medicines Agency |
| --- |
| Domenico Scarlattilaan 6 |
| 1083 HS Amsterdam |
| NIZOZEMSKA |

European Medicines Agency

Domenico Scarlattilaan 6

1083 HS Amsterdam

NIZOZEMSKA

---

(1)  UL L 136, 30.4.2004, str. 1.

---
Erasmo AVILES, Jr., petitioner, v. UNITED STATES.

No. 18-772.

Supreme Court of the United States

April 29, 2019.

Petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit denied.
Billie Jerome ALLEN, petitioner, v. UNITED STATES.

No. 16-8229.

Supreme Court of the United States

Oct. 2, 2017.

Petition for writ of certiorari to the United States Court of Appeals for the Eighth Circuit denied.
Michael PRESLEY, et al., petitioners, v. UNITED STATES.

No. 18-831.

Supreme Court of the United States

March 25, 2019.

Petition for writ of certiorari to the United States Court of Appeals for the Eleventh Circuit denied.
Tommie H. TELFAIR, petitioner, v. UNITED STATES.

No. 18-7840.

Supreme Court of the United States

March 18, 2019.

Petition for writ of certiorari to the United States Court of Appeals for the Third Circuit denied.

Justice KAGAN took no part in the consideration or decision of this petition.
Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of ONEOK Partners, L.P. (the Company) for the
period ending September 30, 2008 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, John W. Gibson, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Report fully complies with the requirements of
section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the Company.



|                       
|-----------------------
|/s/ John W. Gibson     
|John W. Gibson         
|Chief Executive Officer

November 6, 2008

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement required by Section 906, has been provided to ONEOK Partners, L.P. and will be retained by ONEOK Partners, L.P. and furnished to the Securities and Exchange
Commission or its staff upon request.
[Federal Register Volume 87, Number 89 (Monday, May 9, 2022)]
[Notices]
[Page 27563]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-09876]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-18-2022]


Foreign-Trade Zone (FTZ) 22--Chicago, Illinois; Notification of 
Proposed Production Activity; AbbVie, Inc.; (Pharmaceutical Products); 
Chicago, Illinois

    AbbVie, Inc., submitted a notification of proposed production 
activity to the FTZ Board (the Board) for its facilities in Chicago, 
Illinois within Subzone 22S. The notification conforming to the 
requirements of the Board's regulations (15 CFR 400.22) was received on 
April 29, 2022.
    Pursuant to 15 CFR 400.14(b), FTZ production activity would be 
limited to the specific foreign-status material and specific finished 
product described in the submitted notification (summarized below) and 
subsequently authorized by the Board. The benefits that may stem from 
conducting production activity under FTZ procedures are explained in 
the background section of the Board's website--accessible via 
www.trade.gov/ftz. The proposed finished product and material would be 
added to the production authority that the Board previously approved 
for the operation, as reflected on the Board's website.
    The proposed finished product is prolinamide tablets (duty-free).
    The proposed foreign-status material is prolinamide active 
pharmaceutical ingredient (duty rate 3.7%).
    Public comment is invited from interested parties. Submissions 
shall be addressed to the Board's Executive Secretary and sent to: 
<a href="/cdn-cgi/l/email-protection#791f0d03390d0b181d1c571e160f"><span class="__cf_email__" data-cfemail="3d5b49477d494f5c5958135a524b">[email protected]</span></a>. The closing period for their receipt is June 21, 2022.
    A copy of the notification will be available for public inspection 
in the ``Online FTZ Information System'' section of the Board's 
website.
    For further information, contact Christopher Wedderburn at 
<a href="/cdn-cgi/l/email-protection#7132190318025f2614151514031304031f3105031015145f161e07"><span class="__cf_email__" data-cfemail="bcffd4ced5cf92ebd9d8d8d9cedec9ced2fcc8ceddd8d992dbd3ca">[email protected]</span></a>.

    Dated: May 4, 2022.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2022-09876 Filed 5-6-22; 8:45 am]
BILLING CODE 3510-DS-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
```

[Congressional Bills 106th Congress]
[From the U.S. Government Publishing Office]
[H.R. 158 Reported in Senate (RS)]

                                                        Calendar No. 60
106th CONGRESS
  1st Session
                                H. R. 158

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                           February 24, 1999

 Received; read twice and referred to the Committee on Environment and 
                              Public Works

                             March 17, 1999

               Reported by Mr. Chafee, without amendment

_______________________________________________________________________

                                 AN ACT

 
  To designate the United States courthouse located at 316 North 26th 
  Street in Billings, Montana, as the ``James F. Battin United States 
                             Courthouse''.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. DESIGNATION.

    The United States courthouse located at 316 North 26th Street in 
Billings, Montana, shall be known and designated as the ``James F. 
Battin United States Courthouse''.

SEC. 2. REFERENCES.

    Any reference in a law, map, regulation, document, paper, or other 
record of the United States to the United States courthouse referred to 
in section 1 shall be deemed to be a reference to the ``James F. Battin 
United States Courthouse''.

            Passed the House of Representatives February 23, 1999.

            Attest:

                                                 JEFF TRANDAHL,

                                                                 Clerk.
                                     

                                                        Calendar No. 60

106th CONGRESS

  1st Session

                               H. R. 158

_______________________________________________________________________

                                 AN ACT

  To designate the United States courthouse located at 316 North 26th 
  Street in Billings, Montana, as the ``James F. Battin United States 
                             Courthouse''.

_______________________________________________________________________

                             March 17, 1999

                       Reported without amendment
```
Exhibit No. 10(a)
**English Language Summary of Sale and Leaseback Agreement*******
On February 18, 2008, Digi International GmbH, a subsidiary of Digi International Inc. (“Digi”) entered into a bindingcontract for the sale of its building (the “Building”) to Deutsche Structured Finance GmbH & Co. Alphard KG (“DSF”).On the same date, DIGI signed a leaseback agreement with DSF to lease back a part of the building. The Building islocated at Joseph-von-Fraunhofer-Str. 23, D-44227 Dortmund, Germany.
Both parties agreed to the following:
 1. **SALE OF THE BUILDING**. DSF will purchase the building for 4,500,000 Euros.
 2. **TRANSFER OF OWNERSHIP**. The ownership of the Building is transferred at the date of payment. The duedate of the payment is 10 days after certain common legal criteria per the contract have been met. Thetransfer of ownership is expected to take place in the month of March, 2008.
 3. **WITHHOLDING AMOUNTS**. DSF can withhold from the purchase price an amount of 266,260 Euros (see Item 4below), the temporary guarantee of the rental deposit for the second tenant for the rental agreement betweenthe second tenant and DSF (25,000 Euros) and the handover of building plans and other certain documentationregarding the building (7,500 Euros).
 4. **LEASEBACK AGREEMENT**. The effective date of the Leaseback Agreement will be the transfer of ownershipdate. As per the agreement, DIGI will lease back 1,996 square meters, which represents approximately 40% ofthe total building space. The initial period of the contract is 5 years with a renewal option of anadditional 5 years, if DSF is notified 12 months before the end of the initial lease term. The monthly rentexcluding overhead expenses is 20,100 Euros. Rental payments may be adjusted along with the consumer priceindex. Along with the leaseback agreement, DIGI will deposit 266,260 Euros as a security deposit into aninterest bearing bank account at Deutsche Bank, Dortmund.
The Sale and Leaseback Agreement also contains provisions with respect to other obligations of the parties to eachother, including various covenants and conditions to close, the governing law and other miscellaneous matters.
In addition, the Sale and Leaseback Agreement also contains several addendums, which have been omitted from thissummary. These addendums include the following:
 1. Table of existing lease agreements
 2. New lease agreement between Digi and DSF and also between second tenant and DSF which also includes floorand occupancy plans, summary of space leased, requirements for the deposit given by Digi (see Item 4 above),regulations on how occupancy costs are compiled, and tenant occupancy rules
 3. Documentary requirements including general requirements, maps of the land parcel, building floor plans,and technical documentation.
 4. Document stating that the signers representing DSF are authorized to sign the sale agreement.
 * This document is an English Language summary of an originaldocument in the German Language.
AMENDMENT NO. 2 TO THE

SHARE EXCHANGE AGREEMENT

THIS AMENDMENT NO. 2 (this "Amendment") is entered into this 31st day of October 1999, as an amendment to that certain Share Exchange Agreement dated 5th day of May 1998 entered into by and between LAXARCO HOLDING LIMITED, a
company incorporated under the laws of the Republic of Cyprus ("Laxarco"), CARBON RESOURCES LIMITED, a company incorporated under the laws of the Republic of Cyprus ("Carbon"), and SYNERGY TECHNOLOGIES CORPORATION, previously known as AUTOMATED TRANSFER
SYSTEMS CORPORATION, a Colorado corporation ("Synergy") and STONE CANYON RESOURCES, LTD., a company organized under the laws of the Province of Alberta, Canada ("Stone Canyon") as amended by Amendment No. 1 thereto dated June 25, 1999 (the "Agreement").

WHEREAS, the parties, having entered into the Agreement, now wish to amend certain provisions of the Agreement and mutually agree to certain waivers of possible breaches thereunder.

THEREFORE BE IT RESOLVED that the Agreement hereby is amended as set forth below by this Amendment and shall remain in full force and effect, except only to the extent provided herein..

1. 	Subsection (f) of Section 1.1 of the Agreement is hereby amended to read in its entirety as follows:

"(f) "Company's Shares" means 10,000,000 fully paid, non-assessable shares of restricted common stock of the Company to be allotted and issued to Laxarco pursuant to Article 2 hereof, and which will be held in
escrow pursuant to the terms of the Escrow Agreement; provided, however, that until the time that such shares are released from escrow pursuant to the Escrow Agreement, the Company covenants and warrants that such shares shall be subject to anti-dilution rights, meaning that any issuance
of shares, exchange of shares, stock split, reverse stock split, authorization of any new class of common or preferred stock or any other form of recapitalization, shall not occur unless a corresponding issuance of stock is made to Laxarco, subject to the
Escrow Agreement, so that after such corresponding issuance Laxarco holds fifty-one percent (51%) of the outstanding capital stock of the Company."

WITNESS WHEREOF the parties hereto have set their hand and seal as of the day and year first above written.

LAXARCO HOLDING LIMITED, 

a Cyprus corporation

By: /s/PANAYIOTA PIFIANI

Name: Panayiota Pifani

Title: Director



CARBON RESOURCES LIMITED, 

a Cyprus corporation

By: /s/THOMAS E. COOLEY

Name: Thomas E. Cooley

Title: Director



SYNERGY TECHNOLOGIES CORPORATION, 

a Colorado corporation

By: /s/CAMERON HAWORTH

Name: Cameron Haworth

Title: President



STONE CANYON RESOURCES, LTD., 

an Alberta corporation

By: /s/JACQUELINE DANFORTH

Name: Jacqueline Danforth

Title: Secretary/Treasurer
Exhibit 32.1

**CERTIFICATION PURSUANT TO  18 U.S.C. SECTION 1350,  AS ADOPTED PURSUANT TO  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

        In connection with the Quarterly Report of Timeline, Inc. (the “Company”) on Form 10-QSB for the period ended December 31, 2003 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Charles R. Osenbaugh, President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

        (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

        (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

| /s/ CHARLES R. OSENBAUGH                                          |   | Date:  February 12, 2004 |
|-------------------------------------------------------------------|--------|------------------------------------|
|                                                                   |   |                               |
| **Charles R. Osenbaugh,   President and Chief Financial Officer** |   |                               |
|                                                              |   |                               |

30
**EXHIBIT 32.1****CERTIFICATIONS UNDER SECTION 906**     Pursuant to section 906 of the Sarbanes-Oxley Act of 2002(subsections (a) and (b) of section 1350,chapter 63 of title 18, United States Code), theundersigned officer of Alloy, Inc., a Delaware corporation (the“Company”), does hereby certify, to suchofficer’s knowledge, that:     The Annual Report for the year ended January 31, 2005 (the“Form 10-K”) of the Company fully complies withthe requirements of Section 13(a) or 15(d) of theSecurities Exchange Act of 1934, and the information containedin the Form 10-K fairly presents, in all material respects,the financial condition and results of operations of the Company.     /s/ Matthew C. Diamond       Matthew C. Diamond *Chief Executive Officer*Dated: April 15, 2005     A signed original of this written statement required bySection 906 has been provided to the Company and will beretained by the Company and furnished to the Securities andExchange Commission or its staff upon request.
LaVaughn WEATHERLY, petitioner, v. Mark S. INCH, Secretary, Florida Department of Corrections.

No. 18-8263.

Supreme Court of the United States

April 22, 2019.

Petition for writ of certiorari to the United States Court of Appeals for the Eleventh Circuit denied.
Desmond SMITH, petitioner, v. J.A. TERRIS, Warden.

No. 18-7966.

Supreme Court of the United States

March 25, 2019.

Petition for writ of certiorari to the United States Court of Appeals for the Sixth Circuit denied.